Marker Therapeutics is a Houston clinical-stage immuno-oncology company trying to prove that non-engineered multi-antigen T cells can treat lymphoma after CAR-T failure, and the second-quarter print tests whether that program is still being funded like a live trial. Research spending collapsed even as management pointed to a new Department of War award for the lead lymphoma product. The market is not paying for a commercial franchise. It is paying a thin option on whether the APOLLO expansion actually enrolls.
The cash pile at mid-year was $11.9 million. Half-year operating cash use was $5.1 million. That combination funds operations into the second quarter of next year if no new grants arrive, and management still records substantial doubt about going concern. The tension is that the same filing that celebrates grant validation also shows related-party manufacturing payables building while clinical spend falls. A grant committee can like the biology and the company can still be manufacturing fewer batches.
Net loss narrowed to $1.8 million in the quarter as research and development fell to $1.5 million. Grant income of $0.7 million only partly offsets that cut. Authorized shares rose to one hundred thirty million after the May stockholder vote, and the at-the-market facility with H.C. Wainwright sat unused. Does the next data cut show a real dose-expansion cohort, or does the equity remain a cash-backed option that needs another raise before APOLLO can become a registrational program?